# RSV Vaccination in Immunocompromised Patients.

> **NCT06597916** · PHASE2 · RECRUITING · sponsor: **Medical University of Vienna** · enrollment: 200 (estimated)

## Conditions studied

- RSV Infection

## Interventions

- **BIOLOGICAL:** Arexvy powder and suspension for injection

## Key facts

- **NCT ID:** NCT06597916
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-19
- **Primary completion:** 2025-08-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-11-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06597916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06597916, "RSV Vaccination in Immunocompromised Patients.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06597916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*